Centessa IPO Presentation Deck

Offering Summary Issuer Ticker / Exchange ADSs Issued Filing Range Estimated Gross Proceeds Over-Allotment Option Expected Pricing Use of Proceeds Lock-Up Period Bookrunners Centessa Pharmaceuticals plc CNTA / NASDAQ 15,000,000 $18 - $20 $285MM (at midpoint of price range) 15% (100% primary) Thursday, May 27th (post-close) To fund the continued development and pre-commercialization costs of our clinical-stage product candidates, to fund continued development of the other programs in our pipeline, including designing and conducting preclinical studies and clinical trials, as well as funding discovery, manufacturing, research and development; and the remainder for working capital and other general corporate purposes, as well as to fund the acquisition of, and drug development activities related to, new programs 180-day lock-up for directors, executive officers, affiliates and substantially all pre-IPO securityholders Morgan Stanley, Goldman Sachs, Jefferies, Evercore ISI XCENTESSA

View entire presentation